PhD Supervisor, Chief Physician, Associate Professor, Director of Neurocritical Care at the First Affiliated Hospital of the University of Science and Technology of China. Recipient of the 2020 Anhui Province May Day Women's Award.
Education
- 1989-1994: Anhui Medical University, Clinical Medicine, Bachelor's
- 2003-2006: Anhui Medical University, Immunology, Master's
- 2011-2015: Anhui Medical University, Respiratory, PhD
- 2014-2015: University of California, Los Angeles (UCLA), Postdoctoral
Work Experience
- 2006-2016: First Affiliated Hospital of Anhui Medical University, Associate Chief Physician
- 2017-present: First Affiliated Hospital of the University of Science and Technology of China, Department Director/Chief Physician
Academic Achievements and Impact
To date, Dr. Zhou Min has published over 30 SCI papers as corresponding or first author in journals such as Hepatology, Frontiers in Immunology, Neuroendocrinology, Neurocritical Care, and the Journal of Inflammation Research. She has been invited to write 3 review articles and contribute to 5 textbooks and guidelines in critical care medicine. Dr. Zhou has also been invited to deliver keynote presentations at various national and international conferences related to critical care and neurocritical medicine.
Her main projects include 3 general and key projects funded by the National Natural Science Foundation of China, 1 key project funded by the Anhui Provincial Natural Science Foundation, and 1 project supported by the “Keda New Medicine” Foundation. Dr. Zhou holds 2 national invention patents and has received several awards, including the 2020 “Anhui Province May Day Model Worker” honor, the 2008 Anhui Province Science and Technology Progress Third Prize, and has guided 2 new technology and project initiatives at the First Affiliated Hospital of the University of Science and Technology of China.
Ongoing Projects (as Principal Investigator)
- Protective effect of ES-DC immune response mediated by genetic modified β-catenin/Notch Axis in sepsis-induced acute lung injury (National Natural Science Foundation of China, 82241050)
- Total Funding: ¥610,000
- Duration: 2023-01 to 2025-12
Main Research Directions (Recruiting Disciplines) and Content
The research work mainly focuses on immunology/cell biology, basic and clinical research on sepsis, neuroimmune regulation of lung injury, and the mechanisms of brain function and brain diseases.
Admission specialties: Clinical Medicine：Critical Care Medicine (Specialization 2)；Respiratory Medicine (Specialization 2)
Representative Papers (Last Five Years)
1. Mukerabigwi JF, Tang R, Cao Y, Mohammed F, Zhou Q, Zhou M*, Ge Z*. Mitochondria-Targeting Polyprodrugs to Overcome the Drug Resistance of Cancer Cells by Self-Amplified Oxidation-Triggered Drug Release. Bioconjug Chem. 2023 Feb 15;34(2):377-391.
2. Liu S, Lin K, Zhang Y, Gao Y, Wang W, Du M, Jiang T*, Zhou M*, Zhang X*. Prevalence and risk factors of psychotic symptoms in middle-aged patients with first-episode drug-naïve major depressive disorder: A large-scale cross-sectional study. J Affect Disord. 2023 Mar 15;325:102-109.
3. Min Zhou, Min Du, Rui Tang, Hai-Yan Liu, Zhi Gao, Ying Wang, He-Yang You, Ji-Wei Hao, Zong-Shu Ji, Di Wan, Qing-Hong Zhang*. Central GLP-1 Resistance Induced by Severe Traumatic Brain Injury Was Associated with Persistent Hyperglycemia in Humans[J]. Neuroendocrinology, 2023, 113(6): 625-640.
4. Min Du，Qing-Hong Zhang, Rui Tang, Hai-Yan Liu, Zong-Shu Ji, Zhi Gao, Ying Wang, He-Yang You, Ji-Wei Hao, Min Zhou*. Prognostic significance of plasma insulin level for deep venous thrombosis in patients with severe traumatic brain injury in critical care[J]. Neurocritical Care, 2023, 38(2): 263-278.
5. Liu L, Cheng Y, Zhang F, Chen J, Tian P, Shi W, Zhou F, Yang M, Zhou M, Liu B*. IL-2/GM-CSF enhances CXCR3 expression in CAR-T cells via the PI3K/AKT and ERK1/2 pathways. J Cancer Res Clin Oncol. 2023 Aug;149(9):5547-5557.
6. Yu M#, Zhou M#, Li J, Zong R, Yan Y, Kong L et al. Notch-activated mesenchymal stromal/stem cells enhance the protective effect against acetaminophen-induced acute liver injury by activating AMPK/SIRT1 pathway. Stem Cell Research & Therapy 2022; 13(1):1–17.
7. Liu H, Zhou M*. The utility of therapeutic hypothermia on cerebral autoregulation. J Intensive Med. 2022 Oct 4;3(1):27-37.
8. Zhou M, Zhang Y, Tang R, Liu H, Du M, Gao Z, Ji Z, Fang H*. HMGB1/TLR4 Signaling Affects Regulatory T Cells in Acute Lung Injury. J Inflamm Res. 2021 Apr 19;14:1551-1561.
9. Liu L, Yang M, Xu Q, Zhou M, Cheng Y, Xu H, Qin Y, Liu B*. Killing efficiency affected by mutually modulated PD-1 and PD-L1 expression via NKT-hepatoma cell interactions. Immunotherapy. 2021 Feb;13(2):113-123.
10. Ke W, Lu N, Japir AAMM, Zhou Q, Xi L, Wang Y, Dutta D, Zhou M*, Pan Y*, Ge Z*. Length effect of stimuli-responsive block copolymer prodrug filomicelles on drug delivery efficiency. J Control Release. 2020 Feb; 318:67-77.
11. Dutta D, Ke W, Xi L, Yin W, Zhou M*, Ge Z*. Block copolymer prodrugs: Synthesis, self-assembly, and applications for cancer therapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020 Jan;12(1):e1585.
12. Liu L , Yang M , Xu Q , Zhou M , Liu, B*. Killing efficiency affected by mutually modulated PD-1 and PD-L1 expression via NKT-hepatoma cell interactions[J].Immunotherapy, 2020 13(2):113-123.
13. Mohammed F, Ke W, Mukerabigwi JF, M Japir AAM, Ibrahim A, Wang Y, Zha Z, Lu N, Zhou M*, Ge Z*. ROS-Responsive Polymeric Nanocarriers with Photoinduced Exposure of Cell-Penetrating Moieties for Specific Intracellular Drug Delivery. ACS Appl Mater Interfaces. 2019 Sep 4;11(35):31681-31692.
14. Zhou M, Fang H, Du M, Li C, Tang R, Liu H et al. The Modulation of Regulatory T Cells via HMGB1/PTEN/β-Catenin Axis in LPS Induced Acute Lung Injury. Front Immunol 2019; 10:1612.
15. Ji XJ, Hao JW, Li GL, Dong N, Wang XQ, Zhou M, Zhang QH, Yao YM*. Exendin-4 Exacerbates Burn-Induced Morbidity in Mice by Activation of the Sympathetic Nervous System. Mediators Inflamm. 2019 Jan 17;2019:2750528.
Contact Information
E-mail: dminzhou@ustc.edu.cn
Phone: 0551-62284902